Brain Regions Activated during an Auditory Discrimination Task in Insomniac Postmenopausal Patients before and after Hormone Replacement Therapy: Low-Resolution Brain Electromagnetic Tomography Applied to Event-Related Potentials

2004 ◽  
Vol 49 (3) ◽  
pp. 134-153 ◽  
Author(s):  
Peter Anderer ◽  
Bernd Saletu ◽  
Gerda Saletu-Zyhlarz ◽  
Doris Gruber ◽  
Markus Metka ◽  
...  
2003 ◽  
Vol 28 (3) ◽  
pp. 419-445 ◽  
Author(s):  
Peter Anderer ◽  
Heribert V. Semlitsch ◽  
Bernd Saletu ◽  
Gerda Saletu-Zyhlarz ◽  
Doris Gruber ◽  
...  

1993 ◽  
Vol 242 (4) ◽  
pp. 203-208 ◽  
Author(s):  
Akira Iwanami ◽  
Ichiro Suga ◽  
Nobukatsu Kato ◽  
Yoji Nakatani ◽  
Tsuguo Kaneko

2009 ◽  
Vol 24 (S1) ◽  
pp. 1-1
Author(s):  
T. Sumiyoshi ◽  
Y. Higuchi ◽  
T. Itoh ◽  
M. Matsui ◽  
H. Arai ◽  
...  

The purpose of this study was to determine if perospirone, a second generation antipsychotic drug and partial agonist at serotonin-5-HT1A receptors, enhances electrophysiological activity, such as event-related potentials (ERPs), in frontal brain regions, as well as cognitive function in subjects with schizophrenia. P300 current source images were obtained by means of standardized low resolution brain electromagnetic tomography (sLORETA) before and after treatment with perospirone for 6 months. Perospirone significantly increased P300 current source density in the left superior frontal gyrus, and improved positive symptoms and performance on the script tasks, a measure of verbal social cognition. Perospirone also tended to enhance verbal learning memory in patients with schizophrenia. There was a significant correlation between the changes in P300 amplitudes on the left frontal lead and those in social cognition. These results suggest the changes in three-dimensional distribution of cortical activity, as demonstrated by sLORETA, may mediate some of the actions of antipsychotic drugs. the distinct cognition-enhancing profile of perospirone may be related to its actions on 5-HT1A receptors.


Maturitas ◽  
1996 ◽  
Vol 27 ◽  
pp. 170
Author(s):  
J. Paver ◽  
M Borovský ◽  
J Murín ◽  
Z Killinger ◽  
P Ondrejka

2001 ◽  
Vol 101 (5) ◽  
pp. 447-453 ◽  
Author(s):  
Silvia MAFFEI ◽  
Silvia DEL RY ◽  
Concetta PRONTERA ◽  
Aldo CLERICO

The mechanisms that mediate the cardioprotective action of steroid hormones in postmenopausal women are poorly understood. To study the inter-relationship between female steroid hormones and cardiac natriuretic peptides, plasma levels of atrial natriuretic peptide (ANP) and brain natriuretic peptide (BNP) were measured in postmenopausal women, both before and after oestrogen replacement therapy. A total of 22 healthy postmenopausal women (mean age 51.9±4.6 years) were enrolled in the study; all had been postmenopausal for at least 1 year and all reported climacteric symptoms accompanied by increased levels of follicle-stimulating hormone (>30m-i.u./ml) and luteinizing hormone (>20m-i.u./ml), and a reduction in oestradiol (<25pg/ml). All women were given hormone replacement therapy with transdermal oestradiol, either patch (50μg/24 h) or gel (1mg/day), cyclically combined with oral dihydrogesterone (10mg/day for 12 days/month, on days 19-30 of the month). ANP and BNP were measured directly in plasma samples with specific and sensitive immunoradiometric assays before and after hormone replacement therapy (transdermal oestradiol combined with oral dihydrogesterone). Body weight, arterial blood pressure and echocardiographic examination values did not change after hormone replacement therapy. As expected, serum oestradiol increased significantly and gonadotropins decreased as an effect of the hormone replacement therapy. On average, both ANP and BNP had increased significantly after 3 months of hormone replacement therapy [ANP: before treatment, 17.6±9.6pg/ml; after, 23.6±5.6pg/ml (P = 0.0173); BNP: before treatment, 12.6±10.2pg/ml; after, 19.8±14.0pg/ml (P<0.0001)]. Our study indicates that hormone replacement therapy for a period of 3 months induces a rise in the circulating levels of cardiac natriuretic hormones in postmenopausal women. Our data also suggest the working hypothesis that cardiac natriuretic peptides may play an important role in mediating the cardioprotective effects of female steroid sex hormones in women throughout life.


1994 ◽  
Vol 21 (1) ◽  
pp. 103-106 ◽  
Author(s):  
Akira Iwanami ◽  
Toshikazu Shinba ◽  
Michihisa Sumi ◽  
Nobuyuki Ozawa ◽  
Ken-ichi Yamamoto

2006 ◽  
Vol 119 (12) ◽  
pp. 2907-2915 ◽  
Author(s):  
Chantal Mascarenhas ◽  
Mats Lambe ◽  
Rino Bellocco ◽  
Kjell Bergfeldt ◽  
Tomas Riman ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document